NCT02249988已完成2 期
Phase IIB-III Efficacy Study of ABX203 Vaccine as an Adjunct Therapy to Nucleos(t)Ide Analogs to Maintain Control of HBV Replication After Cessation of Treatment in HBeAg Negative Patients With Chronic Hepatitis B
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Abivax S.A.
- 入组人数
- 261
- 试验地点
- 12
- 主要终点
- Percentage of subjects with viral load < 40 IU/mL at Week 48.
研究概览
简要总结
The study is an open-label, randomized, comparative, multicenter clinical trial. The purpose of this study is to assess the efficacy of ABX203, a new chronic hepatitis B therapeutic vaccine administered as an adjunct therapy to nucleos(t)ide analogs (NUCs), in maintaining control of Hepatitis B disease after cessation of treatment with NUCs in subjects with HBeAg negative chronic Hepatitis B.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subject between 18 and 65 years of age at the time of randomization.
- •Must be HBeAg negative and anti-HBe Abs positive for at least 1 year prior to screening and at screening.
- •Has HBV DNA < 40 IU/mL for at least 1 year prior to screening and at screening
- •Has both ALT and AST levels ≤ ULN for at least 1 year prior to screening and at screening.
- •Must be HBsAg positive at screening.
- •Has been treated with NUCs for at least 2 years prior to screening.
- •Has not been treated with PEG-IFN or IFN for at least 1 year prior to screening.
- •For all females, must have a negative serum pregnancy test at screening. For female of childbearing potential, must have been using adequate contraception and must agree to continue to use it during all study period and for 6 months after completion of the study product administration.
- •Has provided written informed consent.
排除标准
- •Has elevated blood levels of alpha-fetoprotein (AFP) (> 500 ng/mL).
- •Has cirrhosis, defined as
- •platelet count < 150,000/mm3, with esophageal varices on imaging and spleen size > 12, or
- •liver stiffness of 11 kilopascal [kPa] as measured by elastography using FibroScan® or .an AST to Platelet Ratio Index (APRI) > 2).
- •Has hepatocellular carcinoma (HCC) (diagnosed by ultrasonography).
- •Has liver decompensation (albumin < 3.5 g/dL and bilirubin ≥1.3 mg/dL).
- •Is Hepatitis C virus (HCV) Ab positive at screening.
- •Is Hepatitis delta virus (HDV) Ab positive at screening.
- •Is Human Immunodeficiency Virus (HIV) Ab positive at screening.
- •Has an immune suppressive disorder or treatment with immunosuppressive drugs.
- •Has been treated with corticosteroids within 12 weeks prior to the first administration of study product, with the exception of topical or inhaled corticosteroids.
- •Has been treated with rituximab.
- •Has other hepatic diseases of different etiology (such as auto-immune hepatitis, toxic hepatitis, Wilson disease, alcoholic or hemochromatosis).
- •Has a history of allergic disease or reactions likely to be exacerbated by any component of the study products.
- •Has a history of a substance abuse (drug or alcohol) problem within the previous 3 years.
研究组 & 干预措施
Group 1 - ABX203 therapeutic Hepatitis B vaccine treatment arm
Experimental
ABX203 therapeutic vaccine in addition to NUCs background therapy
干预措施: ABX203 therapeutic Hepatitis B vaccine treatment arm (Drug)
结局指标
主要结局
Percentage of subjects with viral load < 40 IU/mL at Week 48.
时间窗: Week 48
次要结局
- Clinical response defined as changes in viral load, liver function, time to relapse(Week 48 and Week 96)
- Immune response defined as T-cell response by ICS (CD4 and CD8 to HBcAg and HBsAg)(Week 48)
- Safety assessment will be conducted throughout the study and will include physical examinations, vital signs, clinical laboratory évaluations, and the recording of AEs(Participants will be followed for the duration of their study participation up to 96 weeks)
研究者
研究点 (12)
Loading locations...
相似试验
已完成
2 期
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast CancerMetastatic Breast CancerNCT00370552R-Pharm136
已完成
3 期
Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung CancerNon-small Cell Lung Cancer MetastaticNCT01966003Amgen642
已完成
3 期
Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid TumorsH1N1 Influenza VirusInvasive Solid TumorsNCT01031719Chiltern Pesquisa Clinica Ltda59
已完成
3 期
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation TherapyCerebral Vein ThrombosisDeep Vein ThrombosisHematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmMetastatic Malignant Solid NeoplasmSplanchnic Vein ThrombosisPulmonary EmbolismNCT03080883Academic and Community Cancer Research United370
Unknown
3 期
Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular LymphomaNon-Hodgkins LymphomaNCT00091676Biovest International629